PA5-62768

antibody from Invitrogen Antibodies

Targeting: AGPAT4 dJ473J16.2, LPAAT-delta

Provider product page for PA5-62768

Immunocytochemistry

Immunohistochemistry

Other assay

Antibody data

Antibody Data
Antigen structure
References [1]
Comments [0]
Validations
Immunocytochemistry [1]
Other assay [2]

Submit

Product number: PA5-62768 - Provider product page
Provider: Invitrogen Antibodies
Product name: AGPAT4 Polyclonal Antibody
Antibody type: Polyclonal
Antigen: Recombinant full-length protein
Description: Immunogen sequence: VTEIDKGSAY GNSDSKQKLN D Highest antigen sequence identity to the following orthologs: Mouse - 76%, Rat - 76%.
Reactivity: Human
Host: Rabbit
Isotype: IgG
Vial size: 100 µL
Concentration: 0.1 mg/mL
Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

AGPAT4 protein structure - PA5-62768 shown in red.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 1 Aberrant upregulation of Agpat4 in colorectal cancer cells. a - c Paracarcinoma (Pc) and carcinoma (Ca) tissues were collected from patients with colorectal cancer (CRC) and subjected to RNA-sequencing analysis. Each tested sample was pooled from three individual samples. KEGG ( a ) or GO ( b, c ) pathway enrichment was performed as indicated. The pathways marked by red boxes were focused on in subsequent analyses. b , c The vertical axis indicates the GO term, and the horizontal axis indicates the Rich factor, which is defined as the ratio of enriched gene number to background gene number. The size of the circles indicates the gene number in the GO term, and the color of the circles indicates the false discovery rate (FDR)-corrected P value. d Heat map showing the relative expression of acylglycerol biosynthetic process-related genes in Pc and Ca tissues from CRC patients. e Concentrations of LPA in Pc and Ca tissues from CRC patients. ( n = 6). f - j Relative mRNA levels of AGPAT1, AGPAT2, AGPAT3, AGPAT4, and AGPAT5 in the Pc and Ca tissues from CRC patients. k Representative images showing the immunostaining of AGPAT4 in Pa and Ca tissues from CRC patients. The statistical data were obtained by analyzing 15 pairs of samples from 15 patients. Scale bar represents 200 mum. ( n = 15). The data in ( e - k ) represent the means +- s.e.ms. (** P < 0.01, *** P < 0.005; Student's t test)

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2. Agpat4 silencing in CRC inhibits tumor progression. a Immunoblotting assays of Agpat4 in MC-38 cells transfected with Agpat4 shRNAs (sh-A1, sh-A2, and sh-A3) or the PLKO vector as a control (sh-NC). b Statistical data showing the gray values in a. (n= 3). c Real-time PCR assays of Agpat4 in MC-38 cells transfected with sh-NC, sh-A2, or sh-A3. (n= 6). d Six-week-old male C57BL/6 mice were intraperitoneally inoculated with sh-A2- or sh-NC-transfected MC-38 cells (410^6 cells in 100 µl of PBS for each mouse). Two weeks later, mice were sacrificed, and the tumor nodules were collected and displayed. (n= 4-5). e Six-week-old male C57BL/6 mice were subcutaneously injected with sh-A2- or sh-NC-transfected MC-38 cells (4 10^6 cells in 100 µl of PBS for each mouse) for 15 days. Then, the mice were sacrificed, and the tumors were collected. (n= 5). f Six-week-old male C57BL/6 mice were intraperitoneally inoculated with sh-A3- or sh-NC-transfected MC-38 cells (4 10^6 cells in 100 µl of PBS for each mouse). Two weeks later, the mice were sacrificed, and the tumor nodules were collected and displayed. (n= 4). g Six-week-old male C57BL/6 mice were subcutaneously engrafted with sh-A3- or sh-NC-transfected MC-38 cells (4 10^6 cells in 100 µl of PBS for each mouse) for 15 days. Then, the mice were sacrificed, and the tumors were collected. (n= 3). h Immunoblotting assays of Agpat4 in CT-26 cells transfected with sh-A2 or sh-NC. sh-A2 was used for Agpat4 silencing (sh-Agpa